2021 年 DORIS 系统性红斑狼疮缓解定义：国际工作组的最终建议。
2021 DORIS definition of remission in SLE: final recommendations from an international task force.
机构信息
Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands
Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, Heraklion, Greece.
出版信息
Lupus Sci Med. 2021 Nov;8(1). doi: 10.1136/lupus-2021-000538.
Abstract
OBJECTIVE
To achieve consensus on a definition of remission in SLE (DORIS).
BACKGROUND
Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation.
METHODS
Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on.
RESULTS
Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator's Global Assessment <0.5 (0-3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics.
CONCLUSION
The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.
摘要
目的
就系统性红斑狼疮（DORIS）的缓解定义达成共识。
背景
缓解是患者和照护者的既定目标，但对缓解定义缺乏共识。此前，由患者代表和医学专家组成的国际工作组发布了这样一个定义的框架，但未达成最终建议。
方法
进行了多次系统文献复习，并在适当选择的数据集中检查了具体的研究问题。讨论了研究结果，并重新表述为建议并进行投票。
结果
基于文献和几个系统性红斑狼疮特定数据集的数据，达成了一套建议。最终，DORIS 工作组建议基于临床系统性红斑狼疮疾病活动指数（SLEDAI）=0、评估者整体评估 <0.5（0-3）、泼尼松 5mg/天或更少，以及稳定的抗疟药、免疫抑制剂和生物制剂，制定一个 SLE 缓解的单一定义。
结论
建议在临床护理、教育和研究中使用 2021 年 DORIS 定义的 SLE 缓解，包括临床试验和观察性研究。
相似文献
1
2021 DORIS definition of remission in SLE: final recommendations from an international task force.2021 年 DORIS 系统性红斑狼疮缓解定义：国际工作组的最终建议。
Lupus Sci Med. 2021 Nov;8(1). doi: 10.1136/lupus-2021-000538.
2
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS).SLE 缓解的框架：来自 SLE 缓解定义的大型国际工作组（DORIS）的共识结果。
Ann Rheum Dis. 2017 Mar;76(3):554-561. doi: 10.1136/annrheumdis-2016-209519. Epub 2016 Nov 24.
3
PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS).PReS 认可的国际儿童狼疮 T2T 工作组定义的儿童狼疮低疾病活动状态（cLLDAS）。
Clin Immunol. 2023 May;250:109296. doi: 10.1016/j.clim.2023.109296. Epub 2023 Mar 17.
4
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.中度/重度系统性红斑狼疮的务实目标及其对临床护理和试验设计的意义：持续达到疾病活动反应指数（DORIS）或低疾病活动状态（LLDAS）至少6个月就足够了，而持续达到至少24个月可确保无损伤进展的高特异性。
Ann Rheum Dis. 2024 Mar 12;83(4):464-474. doi: 10.1136/ard-2023-224919.
5
Remission and low disease activity in Polish patients with systemic lupus erythematosus - real-life, five-year follow-up outcomes.波兰系统性红斑狼疮患者的缓解和低疾病活动度——真实生活中的五年随访结果
Eur Rev Med Pharmacol Sci. 2023 Feb;27(3):949-959. doi: 10.26355/eurrev_202302_31188.
6
Defining remission in childhood-onset lupus: PReS-endorsed consensus definitions by an international task force.定义儿童发病狼疮的缓解：PReS 认可的国际工作组共识定义。
Clin Immunol. 2024 Jun;263:110214. doi: 10.1016/j.clim.2024.110214. Epub 2024 Apr 9.
7
Does remission in systemic lupus erythematosus according to the 2021 DORIS definition match the treating rheumatologist's judgement?2021 年 DORIS 定义下的系统性红斑狼疮缓解与治疗风湿病医生的判断是否相符？
Rheumatology (Oxford). 2024 Jan 4;63(1):72-78. doi: 10.1093/rheumatology/kead159.
8
[Low disease activity and remission status of systemic lupus erythematosus in a real-world study].[一项真实世界研究中系统性红斑狼疮的低疾病活动度和缓解状态]
Beijing Da Xue Xue Bao Yi Xue Ban. 2024 Apr 18;56(2):273-278. doi: 10.19723/j.issn.1671-167X.2024.02.011.
9
Remission in SLE-do DORIS criteria match the treating physician's judgment? A cross-sectional study to assess reasons for discordance.SLE 缓解——DORIS 标准与治疗医生的判断相符吗？一项评估不一致原因的横断面研究。
Rheumatology (Oxford). 2021 Sep 1;60(9):4298-4305. doi: 10.1093/rheumatology/keab005.
10
How can we define low disease activity in systemic lupus erythematosus?我们如何定义系统性红斑狼疮的低疾病活动度？
Semin Arthritis Rheum. 2019 Jun;48(6):1035-1040. doi: 10.1016/j.semarthrit.2018.10.013. Epub 2018 Oct 16.
引用本文的文献
1
The LUNET Project: Developing the Italian Systemic Erythematous Lupus Network.LUNET项目：构建意大利系统性红斑狼疮网络。
J Clin Med. 2025 Sep 2;14(17):6197. doi: 10.3390/jcm14176197.
2
Advancing treat-to-target in SLE: a pilot study using a clinical decision support system.系统性红斑狼疮治疗达标进展：一项使用临床决策支持系统的试点研究
Lupus Sci Med. 2025 Aug 22;12(2):e001605. doi: 10.1136/lupus-2025-001605.
3
Post Varicella-Zoster virus transverse myelitis: Diagnostic and therapeutic challenges - A case report and literature review.水痘-带状疱疹病毒感染后横贯性脊髓炎：诊断与治疗挑战——病例报告及文献综述
IDCases. 2025 Jul 29;41:e02336. doi: 10.1016/j.idcr.2025.e02336. eCollection 2025.
4
Long Term Outcomes of Anti-COVID-19 Vaccines in Patients with Systemic Lupus Erythematosus: A Multicentre Study.系统性红斑狼疮患者接种抗COVID-19疫苗的长期结局：一项多中心研究
Vaccines (Basel). 2025 Jul 8;13(7):735. doi: 10.3390/vaccines13070735.
5
Lupus nephritis and U1-RNP-antibodies are associated with low bone mineral density and osteoporosis in patients with systemic lupus erythematosus: baseline findings in a sub-cohort of patients with inflammatory rheumatic diseases.狼疮性肾炎和U1-RNP抗体与系统性红斑狼疮患者的低骨矿物质密度和骨质疏松症相关：炎症性风湿性疾病患者亚组的基线研究结果。
Arthritis Res Ther. 2025 Jul 28;27(1):158. doi: 10.1186/s13075-025-03610-y.
6
Prevalence and outcomes of a pilot definition of severe refractory systemic lupus erythematosus: observations from a multinational Asia-Pacific cohort.重度难治性系统性红斑狼疮初步定义的患病率及转归：来自亚太地区多国队列的观察结果
Arthritis Res Ther. 2025 Jul 23;27(1):155. doi: 10.1186/s13075-025-03622-8.
7
Efficacy and Safety of Biologics for Systemic Lupus Erythematosus (SLE): A Systematic Review and Network Meta-Analysis.生物制剂治疗系统性红斑狼疮（SLE）的疗效与安全性：一项系统评价和网状Meta分析
Clin Rev Allergy Immunol. 2025 Jul 23;68(1):70. doi: 10.1007/s12016-025-09082-x.
8
Advances in the treatment of systemic lupus erythematosus.系统性红斑狼疮治疗的进展
Nat Rev Drug Discov. 2025 Jul 17. doi: 10.1038/s41573-025-01242-0.
9
Achievement and Features Associated with Childhood Definition of Remission in Juvenile-Onset Systemic Lupus Erythematosus.儿童期起病的系统性红斑狼疮缓解定义的相关成就与特征
Turk Arch Pediatr. 2025 Jul 1;60(4):398-403. doi: 10.5152/TurkArchPediatr.2025.25092.
10
Rituximab as the first-line treatment in newly diagnosed systemic lupus erythematosus.利妥昔单抗作为新诊断系统性红斑狼疮的一线治疗药物。
Front Immunol. 2025 Jun 20;16:1599473. doi: 10.3389/fimmu.2025.1599473. eCollection 2025.
本文引用的文献
1
Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort.系统性红斑狼疮缓解：在大型多中心队列中测试不同定义。
Ann Rheum Dis. 2020 Jul;79(7):943-950. doi: 10.1136/annrheumdis-2020-217070. Epub 2020 Apr 22.
2
Treat to Target in Psoriatic Arthritis.靶向治疗银屑病关节炎。
Rheum Dis Clin North Am. 2019 Nov;45(4):505-517. doi: 10.1016/j.rdc.2019.07.002. Epub 2019 Aug 16.
3
Remission and low disease activity state prevent hospitalizations in systemic lupus erythematosus patients.缓解和低疾病活动状态可预防系统性红斑狼疮患者住院。
Lupus. 2019 Oct;28(11):1344-1349. doi: 10.1177/0961203319876998. Epub 2019 Sep 24.
4
Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort.缓解时间和低疾病活动状态（LDAS）与系统性红斑狼疮患者的生活质量改善相关：来自 LUMINA（LXXIX）的结果，一个多民族、多中心的美国队列研究。
RMD Open. 2019 May 23;5(1):e000955. doi: 10.1136/rmdopen-2019-000955. eCollection 2019.
5
Better Health-Related Quality of Life in Systemic Lupus Erythematosus Predicted by Low Disease Activity State/Remission: Data From the Peruvian Almenara Lupus Cohort.低疾病活动状态/缓解预测系统性红斑狼疮患者具有更好的健康相关生活质量：来自秘鲁阿尔梅纳拉狼疮队列的数据。
Arthritis Care Res (Hoboken). 2020 Aug;72(8):1159-1162. doi: 10.1002/acr.24009. Epub 2020 Jul 3.
6
Treat-to-target in rheumatoid arthritis - are we there yet?类风湿关节炎的达标治疗——我们做到了吗？
Nat Rev Rheumatol. 2019 Mar;15(3):180-186. doi: 10.1038/s41584-019-0170-5.
7
Remission and low disease activity state (LDAS) are protective of intermediate and long-term outcomes in SLE patients. Results from LUMINA (LXXVIII), a multiethnic, multicenter US cohort.缓解和低疾病活动状态（LDAS）对系统性红斑狼疮（SLE）患者的中长期预后具有保护作用。这是来自美国一个多民族、多中心队列研究LUMINA（LXXVIII）的结果。
Lupus. 2019 Mar;28(3):423-426. doi: 10.1177/0961203319826693. Epub 2019 Jan 24.
8
The relationship between remission and health-related quality of life in a cohort of SLE patients.SLE 患者队列中缓解与健康相关生活质量的关系。
Rheumatology (Oxford). 2019 Apr 1;58(4):628-635. doi: 10.1093/rheumatology/key349.
9
Development of the Asia Pacific Lupus Collaboration cohort.亚太狼疮协作队列的发展
Int J Rheum Dis. 2019 Mar;22(3):425-433. doi: 10.1111/1756-185X.13431. Epub 2018 Nov 5.
10
Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.比较美国红斑狼疮队列中缓解和狼疮低疾病活动状态在预防损伤方面的作用。
Arthritis Rheumatol. 2018 Nov;70(11):1790-1795. doi: 10.1002/art.40571.
Zotero 插件